CONFERENCE REPORTER
Juan D. Oms, MD, FAPA, explored unmet wants in main depressive dysfunction (MDD) and the significance of novel therapeutic targets in his presentation on the 2025 Southern Florida Psychiatry Convention in West Palm Seaside, Florida.
“We’re transferring from the monoamine mannequin to the glutamate mannequin,” shared Oms, “as a result of so many sufferers have treatment-resistant despair.”
This transfer can also be pushed by the prevalence of anhedonia, shared Oms. Larger ranges of anhedonia in despair have been related to a bigger variety of previous depressive episodes, longer depressive episode size, larger general illness severity, and elevated threat of suicidal behaviors. Longitudinal research additionally counsel that severity of anhedonia predicts a persistence of despair 12 months later.1,2
Moreover, anhedonia is related to antagonistic outcomes in sufferers with MDD, with extra extreme depressive episodes, elevated suicidality, and an general poor prognosis. On a organic stage, sufferers with MDD experiencing anhedonia have increased ranges of inflammatory components, irregular metabolic perform, and hypermetabolism of BDNF.
“Sadly, the present remedy of SSRIs and SNRIs do probably not deal with that part effectively,” stated Oms. “And, on the finish of the day, if you lack pleasure, every part goes on decline: your enjoyment of life, going to work, your loved ones.”
Oms famous we’re seeing an increasing number of brokers obtainable to make use of, whether or not that’s esketamine and ketamine, to transcranial magnetic stimulation, all in service of combatting treatment-resistant despair and fulfilling unmet wants in MDD.
Dr Oms is the residency program director at Southern Winds Hospital, and voluntary assistant professor within the division of psychiatry at Florida Worldwide College in Miami, FL.
References
1. Serretti A.
2. Wu C, Mu Q, Gao W, Lu S.